Market research
SBS.F Stratec SE
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 285M
- P/E ratio
- Not available
- Analyst target
- 25.6
- Dividend yield
- 2.6%
- Beta
- 0.85
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- DE000STRA555
- Market cap
- 285M
- P/E ratio
- Not available
- Analyst target
- 25.6
- Dividend yield
- 2.6%
- Beta
- 0.85
About
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
Research context
Stratec SE appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SBS.F discussion.
5 years, 7 months ago
Stratec SE is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.8.
Stratec SE's total revenue rose by 17.2% to $71M since the same quarter in the previous year.
Its net income has increased by 33.4% to $10M since the same quarter in the previous year.
Finally, its free cash flow grew by 362.3% to $9M since the same quarter in the previous year.
Based on the above factors, Stratec SE gets an overall score of 4/5.